Main Article Content
The aim of this work was to study the effectiveness of lipid-lowering therapy with rosuvastatin in patients with metabolic syndrome (MS). For this purpose, 86 patients with AH of I-III degree and MS aged from 27 to 70 years were examined. It was found that lipid-lowering therapy significantly reduced the level of not only lipids, but also pro-inflammatory cytokines, which in turn confirms their pleiotropic (anti-inflammatory) effect. The data obtained are consistent with the results of a number of studies in which the anti-inflammatory effect of statins is carried out through the suppression of the activity of a number of cytokines, such as TNF-α, IFN-gamma, IL-6, and hsCRP levels. As a result of the obtained lipid-lowering therapy, patients with MS showed a significant decrease in the level of lipid spectrum parameters: total cholesterol by 1.5 times, triglycerides by 1.5 times, low-density lipoprotein cholesterol by 1.8 times, and the atherogenic coefficient by 1.6 times, which indicates a highly effective hypolipidemic effect of rosuvastatin. Along with this, in patients with MS in the dynamics of treatment with rosuvastatin, there was a significant decrease in markers of inflammation CRP by 2 times, IL-6 by 3 times, TNF-a by 2.1 times, which confirms their pleiotropic (anti-inflammatory) effect.